TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Microbix Biosystms ( (TSE:MBX) ) has shared an update.
Microbix Biosystems Inc. has partnered with SEKISUI Diagnostics to support the U.S. commercialization of a molecular point-of-care assay for COVID/Flu diagnosis using the Metrix platform from Aptitude Medical Systems. Microbix will provide its REDxFLOQ QAPs to support SEKISUI’s distribution of the test, which is available under an Emergency-Use Authorization from the U.S. FDA. This collaboration aims to enhance the accuracy and reliability of the test by providing operator-training materials and ensuring compliance with quality systems, thereby strengthening Microbix’s position in the diagnostics industry.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.
Microbix Biosystems’ overall stock score is primarily influenced by its strong financial performance and stability, despite recent revenue challenges. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. The earnings call reflects both immediate challenges and potential for future growth, balancing the overall outlook.
To see Spark’s full report on TSE:MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a life sciences company that creates proprietary biological products for human health. It has over 120 skilled employees and reported revenues of C$ 25.4 million in its latest fiscal year. The company manufactures and exports critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs) and reference materials (QUANTDx). These products support point-of-care testing (POCT) and clinical lab external quality assessment (EQA), enabling assay development and validation, and ensuring the quality of clinical diagnostic workflows. Microbix’s products are available in over 30 countries and are supported by a network of international distributors. The company is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.
Average Trading Volume: 92,458
Technical Sentiment Signal: Sell
Current Market Cap: C$34.12M
For detailed information about MBX stock, go to TipRanks’ Stock Analysis page.